The primary efficacy analysis showed the gedatolisib triplet led to statistically significant and clinically meaningful PFS ...
The FDA has granted Priority Review of Celcuity’s New Drug Application (“NDA”) for gedatolisib in patients with HR+/HER2-/ PIK3CA wild-type (“WT”) ABC and assigned a Prescription Drug User Fee Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results